In 2024 the FDA’s Real‑World Evidence (RWE) program continues to expand, offering manufacturers a new pathway to...
Pipeline
In 2026, precision oncology increasingly relies on multi-omics data coupled with clinical context. Merging single-cell RNA-Seq (scRNA-Seq)...